Ken Aitken – Managing Director – Metgasco (ASX:MEL) is a petroleum (oil and gas) exploration and production company, listed on the Australian Securities Exchange.
Copyright 2023 – Finance News Network
Source: Finance News Network
18 Aug 2022 - eCargo Holdings Limited (ASX:ECG) Group CEO Lawrence Lun discusses the rationale for the sale of digital consultancy company Amblique, how the proceeds will be used, and the roadmap for the coming months.
Read More25 Jul 2023 - BluGlass Limited (ASX:BLG) CEO Jim Haden provides an update on the company, discussing customers and market, product improvements, vertical integration and roadmap.
Read More21 Oct 2024 - Ken Morrison, CEO of the Bradfield Development Authority, discusses building Australia's first new city in a century, a high-tech urban project linked to the new Western Sydney International Airport.
Read More29 Jul 2021 - BARD1 Life Sciences Limited (ASX:BD1) CEO Dr Leearne Hinch introduces the company, discussing its recent capital raising and share purchase plan.
Read More25 Mar 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt provides an update on the company's pipeline of clinical trials, focusing on results in head and neck cancer, lung cancer and breast cancer.
Read More31 07 2024 - Amy Dickinson - Event Manager - Equity Events is a Brisbane based company which specialises in organising investment events for the mining, energy, exploration and industrial sectors.
Read More30 Jul 2024 - Andrew Penkethman - CEO & Managing Director - Ardea Resources (ASX:ARL) is an ASX-listed nickel resources company, with a large portfolio of 100%-controlled West Australian-based projects.
Read More22 Feb 2021 - Sequoia Financial Group Limited (ASX:SEQ) Managing Director Garry Crole talks about the company's strong 1H21 results on the back of increased trading activity, wealth management and continued growth in advisors.
Read More25 Feb 2020 - Noxopharm Limited (ASX:NOX) Chief Medical Officer, Dr Gisela Mautner, talks about results from the company's LuPIN trial in prostate cancer, evaluating its lead product candidate, Veyonda, in combination with 177Lu-PSMA-617, a radiopharmaceutical therapy, in 56 patients with late-stage prostate cancer.
Read More26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
Read More
